Article in Infection and immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Annie Park Moseman *Department of Integrative Immunobiology, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0009-0004-5773-9487
Ching-Wen Chen *Department of Integrative Immunobiology, Duke University School of Medicine, Durham, North Carolina, USA.
Xiaoe LiangDepartment of Integrative Immunobiology, Duke University School of Medicine, Durham, North Carolina, USA.
Dongmei LiaoDepartment of Integrative Immunobiology, Duke University School of Medicine, Durham, North Carolina, USA.
Masayuki KuraokaDepartment of Integrative Immunobiology, Duke University School of Medicine, Durham, North Carolina, USA.
E Ashley MosemanDepartment of Integrative Immunobiology, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0002-6064-6116
Funding
Optimizing the Generation of Monoclonal Antibodies for Prevention and Treatment of HSV DiseaseR01AI177673 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Betsy C. Herold, Masayuki Kuraoka · 2023 to 2026
$2.4M
Treatment of Primary Amoebic Meningoencephalitis via Modulation of Antibody Effector FunctionsR01NS121067 · NINDS · DUKE UNIVERSITY · PI MOSEMAN, E. ASHLEY · 2021 to 2025
$2.0M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI177673HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) NS121067NIAID NIH HHS R01 AI177673NINDS NIH HHS R01 NS121067
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Therapeutic glycan-specific antibody binding mediates protection during primary amoebic meningoencephalitis. · full record | OpenQuestion